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Abstract
Background: Dengue is a major public health problem worldwide, especially in the tropical and subtropical
regions of the world. Infection with a single Dengue virus (DENV) serotype causes a mild, self-limiting febrile illness
called dengue fever. However, a subset of patients experiencing secondary infection with a different serotype
progresses to the severe form of the disease, dengue hemorrhagic fever/dengue shock syndrome. Currently, there
are no licensed vaccines or antiviral drugs to prevent or treat dengue infections. Biodegradable nanoparticles
coated with proteins represent a promising method for in vivo delivery of vaccines.
Findings: Here, we used a murine model to evaluate the IgG production after administration of inactivated DENV
corresponding to all four serotypes adsorbed to bovine serum albumin nanoparticles. This formulation induced a
production of anti-DENV IgG antibodies (p < 0.001). However, plaque reduction neutralization assays with the four
DENV serotypes revealed that these antibodies have no neutralizing activity in the dilutions tested.
Conclusions: Our results show that while the nanoparticle system induces humoral responses against DENV,
further investigation with different DENV antigens will be required to improve immunogenicity, epitope specicity,
and functional activity to make this platform a viable option for DENV vaccines.
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Background
Dengue virus (DENV) is a major public health problem
worldwide, especially in the tropical and subtropical
areas with around 2.5 billion people living in areas at
risk [1]. The disease is caused by a positive sense, sin-
gle-stranded RNA virus that belongs to genus Flavivirus,
family Flaviviridae. DENV is transmitted to humans pri-
marily after a bite by an infected Aedes aegypti and
Aedes albopictus mosquitoes. Infection with one of the
DENV serotypes (DENV-1, -2, -3 and -4) causes a mild,
self-limiting febrile illness called dengue fever (DF).
However, after secondary infection, a small subset
(~0.5%) develop the dengue hemorrhagic fever (DHF)/
dengue shock syndrome (DSS), the severe form of the
disease [2].
While vaccines could potentially prevent DENV infec-
tion or disease in humans, none are currently licensed
despite decades of intensive research [3]. To date, sev-
eral approaches have been developed towards generating
a tetravalent anti-DENV vaccine including live-attenu-
ated strains, inactivated strains, subunit DNA or plasmid
vaccines, and recombinant proteins [4]. Our group has
begun vaccine studies using a unique platform, the
nanoparticles. Biodegradable nanoparticles are currently
used as drug carriers or as adjuvants for vaccines [5].
Polymeric nanoparticles with adsorbed or entrapped
antigens represent a novel method for controlling the
release of immunogens and to optimizing the immune
response via selective targeting of the antigen presenting
cells [6]. In this exploratory study we evaluated the anti-
DENV IgG response in mice immunized with bovine
serum albumin nanoparticles adsorbed with all four ser-
otypes of inactivated DENV.* Correspondence: coelho@unifal-mg.edu.br1Institute of Biomedical Science, Federal University of Alfenas, Minas Gerais,
Brazil
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Methods
Cell culture and virus production
C6/36 Aedes albopictus cells were grown in L-15 med-
ium (Cultilab, Brazil) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS) (Cultilab, Brazil),
100 μg/mL penicillin and 100 μg/mL streptomycin at
28°C. The DENV-1, 2, 3 and 4 were isolated from den-
gue infected patients in Brazil and were kindly donated
by Dr. Erna G. Kroon (Lab Virus, Federal University of
Minas Gerais, Brazil). The propagation of each serotype
of DENV was carried out in separate C6/36 cell cultures
flasks. The cells were infected with DENV-1, 2, 3 or 4 at
a multiplicity of infection (MOI) of 0.1 and incubated at
28°C for a week. After the development of cell syncytia,
the supernatants were harvested, and titrated by stan-
dard plaque assay in LLC-MK2 cells [7]. Heat-inacti-
vated virus was prepared by incubating virus samples in
a 55°C water bath for one hour as described previously
[8].
Nanoparticle preparation and characterization
The nanoparticles were obtained by the addition of
ethanol dropwise (ethanol:water relation 1,5:1) to an
aqueous solution of bovine serum albumin (BSA) (2%
w/v). The coacervates were hardened by adding 50 μL
of 25% glutaraldehyde while stirring for 2 hours at room
temperature. The BSA-nanoparticles were purified by
three cycles of centrifugation at 13,000 g for 30 minutes
to eliminate free BSA and the excess of the crosslinking
agent. The supernatants were removed and the pellets
resuspended in sterile PBS (final concentration of 20
mg/mL). For adsorption of inactivated viral particles to
the surface of the nanoparticles (NP+DENV), 1 mL sus-
pension of the tetravalent DENV antigenic suspension
(equivalent of 1. 2 × 104 plaque forming units (PFU) for
each serotype) was incubated with 1 mL of NP at 20
mg/mL. After rapid homogenization (30 seconds), the
nanoparticles were purified by three successive centrifu-
gations, each at 13,000 g for 30 minutes, 20°C. The
supernatants were collected after each centrifugation
and tested by Bradford assay [9]. To determine the
amount of protein adsorbed to the nanoparticles, a col-
orimetric assay was used and compared to the input
protein and that recovered in the supernatants after
centrifugation.
The presence of viral particles on the surface of NPs
was demonstrated by ELISA assays using the NP+DENV
as antigen. Briefly, 96-well microtiter plates were coated
with NP+DENV (200 μg/well) in carbonate buffer, incu-
bated overnight at 4°C and then washed with PBS con-
taining 0.05% Tween-20 (PBST). Subsequently, the
plates were blocked with 100 μl/well of blocking buffer
(5% dry milk in PBST) for 2 h at 37°C. After three
washes, 100 μl of monoclonal anti-DENV-1 (E95), anti-
DENV-2 (E96), anti-DENV-3 (E51) or DENV-4 (E88)
was added at 1 μg/mL [10-12] in triplicate and incu-
bated for 1 h at 37°C. After three washes, the plates
were incubated for 1 hour at 37°C with 100 μl/well of
horseradish-peroxidase (HRP)-labeled anti-mouse IgG
(Sigma) diluted 1:5000 in PBST. After three additional
washes, the plates were incubated for 15 minutes with
0.1 ml of 0.045% H2O2 and 0.4 mg/ml of o-phenylene-
diaminedihydrochloride (OPD) in phosphate-citrate buf-
fer (0.1 M citric acid, 0.2 M sodium phosphate dibasic,
pH 5.0). The reaction was stopped by adding 50 μl of 2
M H2SO4. The optical densities were read at 450 nm
with a microplate reader. The zeta potential of the NPs
were determined with a Zetasizer 3000 HS (Malvern
Instruments, UK). The surface morphology and the dia-
meter of the formulated nanoparticles were visualized
by scanning electron microscopy (Model JEOL 560).
Immunization protocol and quantification of anti-DENV
and anti-BSA IgG
Six-week-old male Swiss Webster mice were used for
immunizations. All mice were maintained with free
access to sterile food and water, and protocols were
approved by the local Animal Experimentation Ethics
Committee. Mice were immunized via the subcutaneous
route using 100 μg of NP (n = 15) or NP+DENV (n =
20) on days 0, 7 and 14. The mice were sacrificed 7
days after the last immunization (at day 21). Additional
mice were immunized with PBS (negative control) (n =
10) or 1.2 × 104 PFU of the tetravalent DENV heat-inac-
tivated antigenic suspension (positive control) (n = 10).
Blood was collected by cardiac puncture and sera were
separated for ELISA. To perform IgG quantification, 96-
well microtiter plates were coated with 500 PFU/well of
the inactivated DENV particles (serotypes 1 to 4) in car-
bonate buffer or BSA (2 μg/well). An ELISA was per-
formed exactly as described above for quantitation of
viral particles on NP, except virions were captured
directly and sera from mice were used as the primary
antibody. An analysis of ELISA results was performed
using analysis of variance (ANOVA), and the differences
between groups were evaluated with Tukey’s test.
Plaque Reduction Neutralization assay (PRNA)
Briefly, heat-inactivated mouse sera were serially diluted
two-fold from 1:20 to 1:320 in media and then mixed
with a single DENV serotype (20 to 50 PFU/well) and
incubated for 1 hour at 37°C. The mixture was inocu-
lated onto LLC-MK2 cells in 24-well plates. Plates were
incubated for 1 h before media was aspirated and
replaced with 0.5 mL of 0.8% carboximethylcellulose
medium (with 2% FBS). The plates are incubated at 37°
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C (5% CO2) for five days. At that time, cells were
stained with a crystal violet solution (0.5% crystal violet,
10% ethanol and 1% paraformaldehyde) for 20 minutes,
washed again, and the viral plaques were counted. The
positive-control serum sample was a serum sample
derived from a human patient and the antibody titers
were 1:40 for DENV-1 and 1:20 for DENV-2, 3 and 4.
Experiments were performed in duplicate.
Results and discussion
The development of a dengue vaccine is considered
challenging, because it must provide protective immu-
nity against the four serotypes, without causing adverse
side effects associated with incomplete immunity against
a single serotype. Although the pathogenesis of the dis-
ease and protection mechanisms are not fully under-
stood, the production of neutralizing antibodies is
believed to be essential to the effectiveness of a DENV
vaccine [13]. Biodegradable nanoparticles made by BSA
coated with proteins represent a promising method for
in vivo delivery of protein vaccines directly to the
immune system.
The resulting BSA nanoparticles had a mean diameter
of 686.9 nm and the mean zeta potential of 35.8 mV.
Scanning electron micrograph images of the nanoparti-
cles revealed their regular spherical shape (Figure 1A).
The BSA nanoparticle adsorbed 28.8 ± 6.2% of the total
proteins present in the tetravalent DENV antigenic sus-
pension, and the presence of the inactivated viral parti-
cles on the surface of the NPs was demonstrated by a
conventional ELISA assay using monoclonal antibodies
against all four DENV serotypes. As shown (Figure 1B),
all four DENV serotypes were detected on the surface of
nanoparticles. The adsorption process could be attribu-
ted to the force of attraction between virions and BSA.
Analogously, hepatitis B virus is able to interact with
albumin via its surface proteins, suggesting that the
same mechanism could occur between NPs BSA and
inactivated DENV viral particles [14].
To investigate if this formulation induced antibody
production, groups of outbred Swiss Webster mice
were inoculated with 100 μg of NP+DNV per mouse,
1, 2 or 3 times, at one week intervals. As a control
group, mice were inoculated with an empty NP (naive
group) or with 1.2 × 104 PFU of tetravalent DENV
antigenic heat-inactivated suspension (positive control).
We observed a robust production of anti-DENV IgG
antibodies (P < 0.001) in the mice immunized with NP
+DENV (Figure 2A). In contrast, the empty NP or NP
+DENV failed to induce an anti-BSA antibody
response, confirming the relatively poor immunogeni-
city of BSA. Despite a relatively high level of anti-
DENV antibodies in the immunized mice (NP+DENV),
the PRNT showed an absence (PRNA50 < 1/20) of
neutralizing activity in the serum of these animals in
all dilutions tested (data not showed), although we
cannot rule out the possibility of some neutralizing
activity in dilutions below 1:20. Recent studies indicate
that the antibody response to DENV infection consists
of a minor population of strongly neutralizing antibody
and a major population of cross-reactive, non-neutra-
lizing antibodies (both prM and E) with potential for
enhancement of virus infection and disease [15-17].
However, if a high concentration of all DENV sero-
types (above 1.2 × 104 pfu/mL) was used in the
adsorption step or a larger concentration of NP
+DENV was used in this study, these antibodies could
have a neutralizing activity. As nanoparticles are pha-
gocytosed by dendritic cells and other antigen-present-
ing cells (APCs), the adjuvant effect of BSA-
nanoparticles could be explained by their rapid inter-
nalization by the skin-resident APCs, such as dendritic
cells (DC). The interactions of nanoparticles and DCs
also could be facilitated by the presence of the envel-
ope protein of DENV that was derived in insect cells,
Figure 1 Nanoparticle characterization. A) Scanning electronic
microscopy of the BSA nanoparticles. B) Adsorption of DENV onto
the surface of BSA nanoparticles. BSA nanoparticles were incubated
with the tetravalent solution of inactivated DENV and later purified
by three cycles of centrifugation. The presence of viral particles on
the surface of NPs was demonstrated by ELISA assays using
monoclonal antibodies against DENV-1, 2, 3 or 4. Bars represent the
mean of data collected from three independent experiments.
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and thus displays high mannose carbohydrates. The
DENV E protein is the only glycoprotein exposed on
the surface of mature DENV virions and is responsible
for attachment to the host cell surface and also plays
an important role in viral entry [18]. Studies have
shown that this protein binds to the receptors DC-
SIGN (CD209) and the mannose receptor and facili-
tates the infection of myeloid cells [18-21]. Another
factor that may contribute to the increased production
of IgG anti-DENV is innate immune signaling via toll
like receptor 7 (TLR7). Inactivated viral particles pre-
sent on the surface of the NP have single-stranded
RNA, which can activate TLR7 to induce the synthesis
of pro-inflammatory cytokines [22] that enhances
antibody responses. A similar mechanism was
described by Geeraedts and colleagues using whole
inactivated influenza virus. They demonstrate that the
viral RNA present in inactivated virus particles could
trigger TLR7 to augment the adaptive humoral
responses [23].
Conclusions
Thus, nanoparticles can induce anti-DENV antibodies
readily, although further studies in antigen formulation
will be required to induce the production of neutralizing
antibodies against all four DENV serotypes.
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